Telithromycin: The first ketolide for the treatment of respiratory infections

American Journal of Health-System Pharmacy

Volumn 62, Issue 9, 2005, Pages 905-916

  Kasbekar, Nishaminy ^a   Acharya, Pinak S ^b  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^b UPMC

Author keywords

Dosage; Drug administration; Drug interactions; Ketolides; Mechanism of action; Pharmacokinetics; Resistance; Respiratory tract infections; Spectrum microbial; Telithromycin; Toxicity

Indexed keywords

ANTACID AGENT; CARBAMAZEPINE; CISAPRIDE; CLARITHROMYCIN; DOFETILIDE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PROCAINAMIDE; QUINIDINE; RANITIDINE; RIFAMPICIN; TELITHROMYCIN; WARFARIN;

ANOREXIA; ANTIMICROBIAL ACTIVITY; BACTERIAL ARTHRITIS; CHRONIC BRONCHITIS; COMMUNITY ACQUIRED PNEUMONIA; CONVULSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG APPROVAL; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MARKETING; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SURVEILLANCE PROGRAM; DYSGEUSIA; DYSPEPSIA; EMPYEMA; EOSINOPHILIA; FATIGUE; GRAM NEGATIVE SEPSIS; HEADACHE; HEART ARREST; HUMAN; LUNG COLLAPSE; MANIA; MAXILLA SINUSITIS; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; MONARTHRITIS; NAUSEA; NEPHROLITHIASIS; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; RESPIRATORY TRACT INFECTION; REVIEW; TONSILLITIS; TREATMENT INDICATION; VOMITING;

EID: 17844394690     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/62.9.905     Document Type: Review

References (102)

1. Naimi TS, LeDell KH, Como-Sabetti K et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA. 2003; 290:2976-84.
2. Bartlett JG, Dowell SF, Mandell LA et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000; 31:347-82.
3. Doern GV, Pfaller MA, Kugler K et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis. 1998; 27:764-70.
4. Kollef MH, Sherman G, Ward S et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999; 115:462-74.
5. Ewig S, Ruiz M, Torres A et al. Pneumonia acquired in the community through drug resistant Streptococcus pneumoniae. Am J Respir Crit Care Med. 1999; 159:1835-42.
6. Pallares R, Linares J, Vadillo M et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995; 333:474-80.
7. Metlay JP, Hofmann J, Cetron MS et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2000; 30:520-8.
8. Feikin DR, Schuchat A, Kolczak M et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health. 2000; 90:223-9.
9. Lujan M, Gallego M, Fontanals D et al. Prospective observational study of bacteremic pneumococcal pneumonia: effect of discordant therapy on mortality. Crit Care Med. 2004; 32:625-31.
10. Ketek (telithromycin) package insert. Kansas City, MO: Aventis Pharmaceuticals; 2004 Mar.
11. Bryskier A. New research in macrolides and ketolides since 1997. Expert Opin Investig Drugs. 1999; 8:1171-94.
12. Hansen JL, Ippolito JA, Ban N et al. The structures of four macrolide antibiotics bound to the large ribosomal subunit. Mol Cell. 2002; 10:117-28.
13. Hansen LH, Mauvais P, Douthwaite S. The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol Microbiol. 1999; 31:623-31.
14. Champney WS, Tober CL. Inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by 11 different ketolide antibiotics. Curr Microbiol. 1998; 37:418-25.
15. Berisio R, Harms J, Schluenzen F et al. Structural insight into the antibiotic action of telithromycin against resistant mutants. J Bacteriol. 2003; 185:4276-9.
16. Douthwaite S, Hansen LH, Mauvais P. Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Mol Microbiol 2000; 36:183-93.
17. Poehlsgaard J, Douthwaite S. The macrolide binding site on the bacterial ribosome. Curr Drug Targets Infect Disord. 2002; 2:67-78.
18. Skinner R, Cundliffe E, Schmidt FJ. Site of action of a ribosomal RNA methylase responsible for resistance to erythromycin and other antibiotics. J Biol Chem. 1983; 258:12702-6.
19. Vester B, Douthwaite S. Macrolide resistance conferred by base substitutions in 23S rRNA. Antimicrob Agents Chemother. 2001; 45:1-12.
20. Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother. 1995; 39:577-85.
21. Leclercq R, Courvalin P. Bacterial resistance to macrolide, lincosamide and streptogramin antibiotics by target modifications. Antimicrob Agents Chemother.1991; 35:1267-72.
22. Bonnefoy A, Girard AM, Agouridas C et al. Ketolides lack inducibility properties of MLS(B) resistance phenotype. J Antimicrob Chemother. 1997; 40:85-90.
23. Hoban DJ, Wierzbowski AK, Nichol K et al. Macrolide resistant Streptococcus pneumoniae in Canada during 1998-1999; prevalence of mef (A) and erm (B) and susceptibilities to ketolides. Antimicrob Agents Chemother. 2001; 45:2147-50.
24. Nagai K, Hoellman D, Davies T et al. Activity of telithromycin against 26 quinolone-resistant pneumococci with known quinolone-resistance mechanisms. Clin Microbiol Infect. 2001; 7:703-5.
25. Novotny GW, Jakobsen L, Andersen NM et al. Ketolide antimicrobial activity persists after disruption of interactions with Domain II of 23S rRNA. Antimicrob Agents Chemother. 2004; 48:3677-83.
26. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis. 2002; 34:482-92.
27. Retsema J, Fu W. Macrolides: structures and microbial targets. Int J Antimicrob Agents. 2001; 18(suppl 1):S3-10.
28. Zong P, Shortridge VD. The role of efflux in macrolide resistance. Infect Dis Res. 2000; 3:325-9.
29. Berisio R, Harms J, Schluenzen F et al. Structural insight into the antibiotic action of telithromycin against resistant mutants. J Bacteriol. 2003; 185:4276-9.
30. Lorenz J. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory infections. Int J Clin Pract. 2003; 57:519-29.
31. Chollet R, Chevalier J, Bryskier A et al. The AcrAB-TolC pump is involved in macrolide resistance but not in telithromycin efflux in Enterobacter aerogenes and Escherichia coli. Antimicrob Agents Chemother. 2004; 48:3621-4.
32. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from the PROTEKT US 2000-01. J Infect. 2004; 48:56-65.
33. Zhanel GG, Palatnick L, Nichol KA et al. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian respiratory organism susceptibility study, 1997 to 2002. Antimicrob Agents Chemother. 2003; 47:1875-81.
34. Bebear CM, Renaudin H, Bryskier A et al. Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas. Antimicrob Agents Chemother. 2000; 44:1980-2.
35. Hammerschlag MR. Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review. J Antimicrob Chemother. 2000; 45(suppl 1):35-9.
36. Roblin PM, Hammerschlag MR. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1998; 42:1515-6.
37. Strigl S, Roblin PM, Reznik T et al. In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae. Antimicrob Agents Chemother. 2000; 44:1112-3.
38. Farrell DJ, Douthwaite S, Morrissey I et al. Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 Study. Antimicrob Agents Chemother. 2003; 47:1777-83.
39. Weiss K, Guilbault C, Cortes L et al. Genotypic characterization of macrolide-resistant strains of Streptococcus pneumoniae isolated in Quebec, Canada, and in vitro activity of ABT-773 and telithromycin. J Antimicrob Chemother. 2002; 50:403-6.
40. Jorgensen JH, Crawford SA, McElmeel ML et al. Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2004; 48:605-7.
41. Karchmer AW. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US-an update. Clin Infect Dis. 2004; 39(suppl 3):S142-50.
42. Hsueh PR, Teng LJ, Lee CM et al. Telithromycin and quinupristin- dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART program 2001 data. Antimicrob Agents Chemother. 2003; 47:2152-7.
43. Hsueh PR, Teng LJ, Wu TL et al. Telithromycin- and fluoroquinolone- resistant Streptococcus pneumoniae in Taiwan with high prevalence of resistance to macrolides and β-lactams. SMART program 2001 data. Antimicrob Agents Chemother. 2003; 47:2145-51.
44. Shortridge VD, Zhong P, Zhensheng C et al. Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and resistant streptococci and staphylococci. Antimicrob Agents Chemother. 2002; 46:783-6.
45. Felmingham D. Microbiological profile of telithromycin, the first ketolide antimicrobial. Clin Microbiol Infect. 2001; 7(suppl 3):2-10.
46. Culebras E, Rodriguez-Avial I, Betriu C. Macrolide and tetracycline resistance and molecular relationships of clinical strains of Streptococcus agalactiae. Antimicrob Agents Chemother. 2002; 46:1574-6.
47. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother. 1996; 40:1817-24.
48. Tait-Kamradt A, Clancy J, Cronan M et al. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1997; 41:2251-5.
49. Betriu C, Culebras E, Gomez M et al. Erythromycin and clindamycin resistance and telithramycin susceptibility in Streptococcus agalactiae. Antimicrob Agents Chemother. 2003; 47:1112-4
50. Capobianco JO, Cao Z, Shortridge VD et al. Studies of the novel ketolide ABT-773: transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2000; 44:1562-97.
51. Hoban D, Felmingham D. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J Antimicrob Chemother. 2002; 50(suppl S1):49-59.
52. Pankuch GA, Hoellman DB, Lin G et al. Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and Moraxella catarrhalis by MIC determination and time-kill assay. Antimicrob Agents Chemother. 1998; 42:3032-4.
53. Walsh F, Carnegy F, Willcock J et al. Comparative in vitro activity of telithromycin against macrolide-resistant and susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae. J Antimicrob Chemother. 2004; 53:793-6.
54. Betriu C, Redondo M, Boloix A et al. Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci. J Antimicrob Chemother. 2001; 48:911-3.
55. Odenholt I, Lowdin E, Cars O. Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens. Antimicrob Agents Chemother. 2001; 45:23-9.
56. Davies TA, Ednie LM, Hoellmann DM et al. Anti-pneumococcal activity of ABT-773 compared to those of 10 other agents. Antimicrob Agents Chemother. 2000; 44:1894-9.
57. Boswell FJ, Andrews JM, Wise R. Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory tract pathogens, enterococci, and Bacteroides fragilis, demonstrated by studies of time-kill kinetics and postantibiotic effect. J Antimicrob Chemother. 1998; 41:149-53.
58. Dubois J, St-Pierre C. Telithromycin: comparative bactericidal activity and post-antibiotic effect (PAE) against respiratory pathogens. Clin Microbiol Infect. 2000;6(suppl 1):85.
59. Hagberg L, Torres A, van Rensburg D et al. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community acquired pneumonia. Infection. 2002; 30:378-86.
60. Mathers Dunbar L, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther. 2004; 26:48-62.
61. Niederman MS, Chang JR, Stewart J et al. Comparison of hospitalization rates in patients with community acquired pneumonia treated with 10 days of telithromycin or clarithromycin. Curr Med Res Opin. 2004; 20:749-56.
62. Tellier G, Chang JR, Asche CV et al. Comparison of hospitalization rates in patients with community acquired pneumonia treated with telithromycin for 5-7 days or clarithromycin for 10 days. Curr Med Res Opin. 2004; 20:739-47.
63. Tellier G, Niederman MS, Nusrat R et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother. 2004; 54:515-23.
64. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community acquired pneumonia. N Engl J Med. 1997; 336:243-50.
65. Clark JP, Langston E. Ketolides: a new class of antibacterial agents for treatment of community-acquired respiratory tract infections in a primary care setting. Mayo Clin Proc. 2003; 78:1113-24.
66. Aubier M, Aldons PM, Leak A et al. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respir Med. 2002; 96:862-71.
67. Zervos MJ, Heyder AM, Leroy B. Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis. J Int Med Res. 2003; 31:157-69.
68. Luterman M, Tellier G, Lasko B et al. Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitis. Ear Nose Throat J. 2003; 82:576-90.
69. Buchanan PP, Stephens TA, Leroy B. A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis. Am J Rhinol. 2003; 17:369-77.
70. Roos K, Brunswig-Pitschner C, Kostrica R et al. Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis. Chemotherapy. 2002; 48:100-8.
71. Ragnar Noorby S, Rabie WJ, Bacart P et al. Efficacy of short-course therapy with the ketolide telithromycin compared with 10 days of penicillin V for the treatment of pharyngitis/tonsillitis. Scand J Infect Dis. 2002; 33:883-90.
72. Ragnar Noorby S, Chang J, Stewart JA et al. Relief of symptoms in patients with Group A β-hemolytic Streptococcus tonsillopharyngitis: comparison between telithromycin and penicillin V. Scand J Infect Dis. 2003; 35:223-5.
73. Namour F, Wessels DH, Pascual MH et al. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob Agents Chemother. 2001; 45:170-5.
74. Perret C, Lenfant B, Weinling E et al. Pharmacokinetics and absolute oral bioavailability of an 800-mg oral dose of telithromycin in healthy young and elderly volunteers. Chemotherapy. 2002; 48:217-23.
75. Bhargava V, Lenfant B, Perret C et al. Lack of the effect of food on the bioavailability of a new ketolide antibacterial, telithromycin. Scand J Infect Dis. 2002; 34:823-6.
76. Lippert C, Leese PT, Sultan E. Effect of gastric pH on the bioavailability of telithromycin (HMR 3647). Clin Microbiol Infect. 2001; 7(suppl 1):267.
77. Namour F, Sultan E, Pascual MH et al. Penetration of telithromycin (HMR 3647), a new ketolide antimicrobial into inflammatory blister fluid following oral administration. J Antimicrob Chemother. 2002; 49:1035-8.
78. Muller-Serieys C, Andrews J, Vacheron F et al. Tissue kinetics of telithromycin, the first ketolide antibacterial. J Antimicrob Chemother. 2004; 53:149-57.
79. Rodvold KA, Gotfried MH, Danziger LH et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother. 1997; 41:1399-402.
80. Rodvold KA, Danziger LH, Gotfried MH. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother. 2003; 47:2450-7.
81. Muller-Serieys C, Soler P, Cantalloube C et al. Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). Antimicrob Agents Chemother. 2001; 45:3104-8.
82. Seral C, Van Bambeke F, Tulkens PM. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob Agents Chemother. 2003; 47:2283-92.
83. Khair OA, Andrews JM, Honeybourne D et al. Lung concentrations of telithromycin after oral dosing. J Antimicrob Chemother. 2001; 47:837-40.
84. Olsen KM, San Pedro GS, Gann LP et al. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob Agents Chemother. 1996; 40:2582-5.
85. Lode H. The pharmacokinetics of azithromycin and their clinical significance. Eur J Clin Microbiol Infect Dis. 1991; 10:807-12.
86. Conte JE, Golden JA, Duncan S et al. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob Agents Chemother. 1995; 39:334-8.
87. Fish DN, Gotfried MH, Danziger LH et al. Penetration of clarithromycin into lung tissues from patients undergoing lung resection. Antimicrob Agents Chemother. 1994; 38:876-8.
88. Baldwin DR, Wise R, Andrews JM et al. Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J. 1990; 3:886-90.
89. Edlund C, Alvan G, Barkholt L et al. Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora. J Antimicrob Chemother. 2000; 46:741-9.
90. Savolainen S, Mannisto PT, Gordin A et al. Tonsillar penetration of erythromycin and its 2′-acetyl ester in patients with chronic tonsillitis. J Antimicrob Chemother. 1988; 21(suppl D):73-84.
91. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother. 1990; 25:73-82.
92. Fraschini F, Scaglione F, Pintucci G et al. The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. J Antimicrob Chemother. 1991; 27:61-5.
93. Cantalloube C, Bhargava V, Sultan E et al. Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment. Int J Antimicrob Agents. 2003; 22:112-21.
94. Gattringer R, Urbauer E, Traunmuller F et al. Pharmacokinetics of telithromycin in plasma and soft tissues after single-dose administration to healthy volunteers. Antimicrob Agents Chemother. 2004; 48:4650-3.
95. Sultan E, Lenfant B, Wable C et al. Pharmacokinetic profile of HMR 3647 800 mg once-daily in elderly volunteers. J Antimicrob Chemother. 1999; 44(suppl A):54. Abstract.
96. Shi J, Montay G, Chapel S et al. Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment. J Clin Pharmacol. 2004; 44:234-44.
97. Sultan E, Cantalloube C, Patat A et al. Telithromycin (HMR 3647), the first ketolide antimicrobial, does not require dosage adjustment in individuals with hepatic impairment. Clin Microbiol Infect. 2000; 6(suppl 1):203. Abstract.
98. Ketek FDA briefing document. Kansas City, MO: Aventis Pharmaceuticals; 2003 Jan.
99. Quinn J, Ruoff GE, Ziter PS. Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice daily clarithromycin for the treatment of Group A β-hemolytic Streptococcus tonsillitis/pharyngitis: a multicenter, randomized, double-blind, parallel-group study. Clin Ther. 2003; 25:422-43.
100. Pullman J, Champlin J, Vrooman PS Jr. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Int J Clin Pract. 2003; 57:377-84.
101. Nieman RB, Sharma K, Edelberg H et al. Telithromycin and myasthenia gravis. Clin Infect Dis. 2003; 37:1579. Letter.
102. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf. 1998; 18:83-97.